🚀 VC round data is live in beta, check it out!
Keros Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Keros Therapeutics and similar public comparables like Egetis Therapeutics, Coherus Oncology, Transgene, Reig Jofré and more.
Keros Therapeutics Overview
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Founded
2015
HQ
Employees
169
Website
Sectors
Financials (LTM)
Market Cap
$246M
Keros Therapeutics Financials
Keros Therapeutics reported last 12-month revenue of $180M and EBITDA of $30M.
In the same LTM period, Keros Therapeutics generated $180M in gross profit, $30M in EBITDA, and $29M in net income.
Revenue (LTM)
Keros Therapeutics P&L
In the most recent fiscal year, Keros Therapeutics reported revenue of $244M and EBITDA of $71M.
Keros Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $180M | XXX | $244M | XXX | XXX | XXX |
| Gross Profit | $180M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | $30M | XXX | $71M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $29M | XXX | $87M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 36% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Keros Therapeutics Stock Performance
Keros Therapeutics has current market cap of $246M.
Market Cap Evolution
Keros Therapeutics' stock price is $12.50.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $246M | -0.3% | XXX | XXX | XXX | $4.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKeros Therapeutics Valuation Multiples
Keros Therapeutics trades at (0.1x) EV/Revenue multiple, and (0.8x) EV/EBITDA.
EV / Revenue (LTM)
Keros Therapeutics Financial Valuation Multiples
As of April 11, 2026, Keros Therapeutics has market cap of $246M.
Equity research analysts estimate Keros Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Keros Therapeutics has a P/E ratio of 8.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $246M | XXX | $246M | XXX | XXX | XXX |
| EV (current) | ($24M) | XXX | ($24M) | XXX | XXX | XXX |
| EV/Revenue | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBITDA | (0.8x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (2.5x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/Gross Profit | (0.1x) | XXX | — | XXX | XXX | XXX |
| P/E | 8.5x | XXX | 2.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Keros Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Keros Therapeutics Margins & Growth Rates
Keros Therapeutics' revenue in the last 12 month declined by (94%).
Keros Therapeutics' revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.0M for the same period.
Keros Therapeutics' rule of 40 is (867%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Keros Therapeutics' rule of X is (1011%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Keros Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (94%) | XXX | (96%) | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | (365%) | XXX | (211%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (867%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (1011%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 27% | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 69% | XXX | 53% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Keros Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Egetis Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Coherus Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Transgene | XXX | XXX | XXX | XXX | XXX | XXX |
| Reig Jofré | XXX | XXX | XXX | XXX | XXX | XXX |
| Adimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Keros Therapeutics M&A Activity
Keros Therapeutics acquired XXX companies to date.
Last acquisition by Keros Therapeutics was on XXXXXXXX, XXXXX. Keros Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Keros Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKeros Therapeutics Investment Activity
Keros Therapeutics invested in XXX companies to date.
Keros Therapeutics made its latest investment on XXXXXXXX, XXXXX. Keros Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Keros Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Keros Therapeutics
| When was Keros Therapeutics founded? | Keros Therapeutics was founded in 2015. |
| Where is Keros Therapeutics headquartered? | Keros Therapeutics is headquartered in United States. |
| How many employees does Keros Therapeutics have? | As of today, Keros Therapeutics has over 169 employees. |
| Who is the CEO of Keros Therapeutics? | Keros Therapeutics' CEO is Jasbir Seehra. |
| Is Keros Therapeutics publicly listed? | Yes, Keros Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Keros Therapeutics? | Keros Therapeutics trades under KROS ticker. |
| When did Keros Therapeutics go public? | Keros Therapeutics went public in 2020. |
| Who are competitors of Keros Therapeutics? | Keros Therapeutics main competitors are Egetis Therapeutics, Coherus Oncology, Transgene, Reig Jofré. |
| What is the current market cap of Keros Therapeutics? | Keros Therapeutics' current market cap is $246M. |
| What is the current revenue of Keros Therapeutics? | Keros Therapeutics' last 12 months revenue is $180M. |
| What is the current revenue growth of Keros Therapeutics? | Keros Therapeutics revenue growth (NTM/LTM) is (94%). |
| What is the current EV/Revenue multiple of Keros Therapeutics? | Current revenue multiple of Keros Therapeutics is (0.1x). |
| Is Keros Therapeutics profitable? | Yes, Keros Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Keros Therapeutics? | Keros Therapeutics' last 12 months EBITDA is $30M. |
| What is Keros Therapeutics' EBITDA margin? | Keros Therapeutics' last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Keros Therapeutics? | Current EBITDA multiple of Keros Therapeutics is (0.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.